546 related articles for article (PubMed ID: 16387161)
1. Late acute cardiac allograft rejection: new therapeutic options?
Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
[TBL] [Abstract][Full Text] [Related]
2. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
3. Conversion to everolimus in maintenance patients--current clinical strategies.
Pohanka E
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
6. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection?
el Gamel A; Keevil B; Rahman A; Campbell C; Deiraniya A; Yonan N
J Heart Lung Transplant; 1997 Mar; 16(3):268-74. PubMed ID: 9087869
[TBL] [Abstract][Full Text] [Related]
7. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
Lehmkuhl H; Ross H; Eisen H; Valantine H
Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
[TBL] [Abstract][Full Text] [Related]
8. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
Li JT; Danguilan RA; Cabanayan-Casasola CB; Talusan-Tomacruz Y; Ona ET
Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
[TBL] [Abstract][Full Text] [Related]
10. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
Bocchi EA; Ahualli L; Amuchastegui M; Boullon F; Cerutti B; Colque R; Fernandez D; Fiorelli A; Olaya P; Vulcado N; Perrone SV
Transplant Proc; 2006 Apr; 38(3):937-42. PubMed ID: 16647515
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
[TBL] [Abstract][Full Text] [Related]
14. Can cyclosporine blood level be reduced to half after heart transplantation?
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2010 Apr; 42(3):930-3. PubMed ID: 20430207
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
[TBL] [Abstract][Full Text] [Related]
16. Everolimus in lung transplantation in Chile.
Parada MT; Alba A; Sepúlveda C
Transplant Proc; 2010; 42(1):328-30. PubMed ID: 20172343
[TBL] [Abstract][Full Text] [Related]
17. Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen.
Nohria A; Ehtisham J; Ramahi TM
J Heart Lung Transplant; 1998 Sep; 17(9):849-53. PubMed ID: 9773855
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in pediatric de nova renal transplant patients.
Hoyer PF; Ettenger R; Kovarik JM; Webb NJ; Lemire J; Mentser M; Mahan J; Loirat C; Niaudet P; VanDamme-Lombaerts R; Offner G; Wehr S; Moeller V; Mayer H;
Transplantation; 2003 Jun; 75(12):2082-5. PubMed ID: 12829916
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Hummel M
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S196-200; discussion S210-1. PubMed ID: 15774322
[TBL] [Abstract][Full Text] [Related]
20. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation.
Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C
Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
